1. INO-3107 shows loss of detectable HPV-6 in patients. 2. Results to be discussed at American Association for Cancer Research conference. 3. INO focuses on HPV-related diseases and cancer treatments. 4. The abstract highlights T cell activation for clinical responses.
The presentation of positive clinical results can attract investors. Similar past announcements have led to stock price increases.
The results presented could validate INO's approach, attracting attention from investors. Their consistent focus on HPV and cancer treatment enhances the significance of their research outcomes.
Successfully demonstrating efficacy could lead to long-term revenue opportunities. Previous successful trials often bolster long-term company valuation.
PLYMOUTH MEETING, Pa., Feb. 10, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that an abstract describing the immunological activity of INO-3107 will be presented as a poster at the following scientific conference:
American Association for Cancer Research – Immuno-Oncology Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy (February 23-26, 2025)
"Loss of Detectable HPV-6 Following Induction of Emergent T cells in Patients with Durable Complete Clinical Response to Treatment for Recurrent Respiratory Papillomatosis using INO-3107"
The abstract will be made available on INOVIO's website following the conference.
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
Contacts
Media: Jennie Willson, (267) 429-8567, [email protected]
Investors: Peter Vozzo, ICR Healthcare, 443-213-0505, [email protected]
SOURCE INOVIO Pharmaceuticals, Inc.